Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Conjunctivitis Clear all
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

NCT05636228
View directory record Official record
Conditions
Acute Infectious Keratoconjunctivitis
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Glendale, California • Pasadena, California • Largo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT03494504
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

FST-100 in the Treatment of Acute Adenoviral Conjunctivitis

NCT01470664
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100, FST-100 (Component #1), FST-100 Vehicle
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jun 26, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

NCT00941486
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100 Ophthalmic Suspension, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears

NCT00266734
View directory record Official record
Conditions
Acute Conjunctivitis, Adenoviral Conjunctivitis
Interventions
RPS Adeno Detector
Device
Lead sponsor
Rapid Pathogen Screening
Industry
Eligibility
1 Month and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Springfield, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome

NCT02680158
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal, Sham, Oculeve Extranasal
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Waterbury, Connecticut • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

NCT00770133
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen/naphazoline, Naphazoline, Ketotifen, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

FST-100 in the Treatment of Acute Viral Conjunctivitis

NCT01461954
View directory record Official record
Conditions
Acute Viral Conjunctivitis
Interventions
FST-100, FST-100 Vehicle
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

NCT00769886
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01685242
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

NCT01561521
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AKF-1
Drug
Lead sponsor
Akorn, Inc.
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

NCT01470118
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

NCT00424398
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Bepreve, Placebo, Bepotastine Besilate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Artesia, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis

NCT05356793
View directory record Official record
Conditions
Acute Infectious Conjunctivitis (Disorder)
Interventions
SCH-1, Placebo
Drug
Lead sponsor
Sacsh
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson Heights, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

NCT03320434
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
PRT-2761 0.5%, PRT-2761 1%, Patanol, Pred-forte, PRT-2761 0%
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

NCT00241319
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Indianapolis, Indiana • Lewiston, Maine • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Jun 26, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jun 26, 2026, 11:38 AM EDT